New drug combo tested for Tough-to-Treat breast cancers
NCT ID NCT02393794
Summary
This study is testing a combination of three drugs—cisplatin, romidepsin, and nivolumab—for people with advanced triple-negative breast cancer or breast cancer linked to a BRCA gene mutation. The goal is to see if this combination is safe and can help control the cancer in patients whose disease has worsened after standard treatments. The study is in two parts: first finding a safe dose, then testing how well it works.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Kansas Cancer Center - Clinical Research Center
Fairway, Kansas, 66205, United States
-
University of Kansas Cancer Center - Lee's Summit
Lee's Summit, Missouri, 64064, United States
-
University of Kansas Cancer Center - North
Kansas City, Missouri, 64154, United States
-
University of Kansas Cancer Center - Overland Park
Overland Park, Kansas, 66210, United States
-
University of Kansas Cancer Center - South
Kansas City, Missouri, 64131, United States
-
University of Kansas Cancer Center - West
Kansas City, Kansas, 66112, United States
-
University of Kansas Cancer Center - Westwood
Westwood, Kansas, 66205, United States
Conditions
Explore the condition pages connected to this study.